Anuh Pharma Limited (BOM:506260)

Market Cap	8.16B -22.8%
Revenue (ttm)	7.72B +16.7%
Net Income	410.46M -13.3%
EPS	4.10 -13.2%
Shares Out	100.22M
PE Ratio	19.86
Forward PE	n/a
Dividend	1.50 (1.93%)
Ex-Dividend Date	Aug 5, 2026

Volume	7,533
Open	78.95
Previous Close	77.77
Day's Range	78.20 - 81.55
52-Week Range	66.72 - 115.00
Beta	0.44
Analysts	Strong Buy
Price Target	71.25 (-12.51%)
Earnings Date	May 20, 2026

About Anuh Pharma

Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-bacterial, anti-asthmatics, anti-diabetics, intermediates, expectorant, quinolones, anti-malarial, anti-gout, anti-biotic, anti-platelet, and antihistamines; and corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic. The company also develops products, such as coagulants, gastrointestinal, anti convulsants, and cholesterol drugs. It a...

• Industry: Pharmaceutical Preparations
• Founded: 1960
• Employees: 295
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 506260

Financial Performance

In fiscal year 2026, Anuh Pharma's revenue was 7.72 billion, an increase of 16.65% compared to the previous year's 6.62 billion. Earnings were 410.46 million, a decrease of -13.32%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 17, 2026

Data Sources Report a data error